

NHSBT Finance Report

October 2022

Contents	Page
Executive Summary	2
Financial Performance Headlines	3-4
NHSBT – Summary I&E Statement	5
Divisional I&E statements	6-9
Cash & Debtors	10
Contribution Statement	11

Executive Summary

October Results: overall financial position ahead of plan primarily driven by Blood and Group transformation

- Year to date revenue reporting £7.4m ahead of budget, predominately reflecting transformation underspends.
- Capital spend up to October is £3.1m.
- Cash at the end of October was £79m – with +90 day overdue debtors reducing to £0.7m (versus £0.9m at M06)

Blood and Group: latest forecast reports a slight upside from Q2 forecast, but still remains very tight with limited headroom

- The Q2 forecast reported increase costs against budget of £6.4m, utilising the surplus £7m cash reserves delivered through the 2022/23 budget build and the 2021/22 favourable position.
- Latest forecast reports small upsides versus Q2 position, reflecting reduced marketing and transformation spend, although partially offset by additional increases to Blood Supply capacity.
- Transformation plan has been reduced from £17m down to c£12m (£13m reported in Q2 forecast). This implies there will be further £10m of spend over the next 5 months. This will need to be closely monitored against planned milestones at programme and project level.
- Blood cash at the end of March 23 still remains very close to the £10m working capital threshold required, therefore there are limited reserves to absorb any further economic shocks/cost pressures
- **Pressures reflected in the Q2 Blood and Group position include:**
 - Productivity savings in blood collection that will no longer be delivered (£2.0m)
 - A further adverse cost variance of (£3.6m) in Blood Supply as a result of increased resourcing and temporary labours costs in Blood Supply
 - Group Services pressures including; direct marketing (£3.0m), super inflation (gas/electricity) in Estates (£0.7m) and selling annual leave take up (£0.5m).
 - The higher pay award (£2.5m)
 - Unfunded national insurance levy - part year up until the reversal in November (£1.0m)
 - Offset against lower transformation (+£3.9m) and DDTS expenditure (+£3.2m)

ODT: Q2 forecast reports a small operational surplus and a deficit against transformation.

- The forecast deficit reflects transformation which will be funded by cash reserves carried forward from 2021/22. This also includes DCD hearts expenditure, where we are awaiting a decision on additional funding to meet the in year costs (£3.6m).
- Discussions with DHSC continue regarding the need to obtain an early decision on funding for 2023/24 and following years (where the underlying position is a growing deficit).

TES: reporting a forecast shortfall of £1.0m driven by lower than plan cornea activity

- This shortfall is currently being funded by Blood cash reserves

Clinical Services: All business units forecasting to exceed budget contribution this year, with exception of CBC

- CBC reporting an adverse position against plan due to slippages in high value contracts combined with the up front purchase of stock


Plasma: fully funded for 2022/23

- For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.
- Discussions are on going with NHS England to finalise an SLA which will fully fund collection costs from mid 2023/24 onwards.

2022/23 NHSBT Financial Performance Headlines - October 2022


Year to date surplus of £7.2m for NHSBT overall, £7.4m ahead of plan

Blood and Group Net Income & Expenditure (excl. Change Programme and Plasma)




Blood and Group in line with budget, Blood Supply overspends being largely offset by favourable variances in Group Services- detail on page 5 & 6.

Clinical Services Net Income & Expenditure (Business unit contribution)




£0.5m favourable variance – combination of higher activity and vacancies across Business Units – detail on page 7.

Organ Donation & Transplantation Net Funding & Expenditure




ODT broadly in line with plan - detail on page 8

Blood and Group Change Programme Full Year Outturn




Full year forecast £12.3m, versus the £17m plan. The difference is mostly due to re-categorisation of Blood Tech Modernisation expenditure to capital.

NHSBT Cash Flow 2022/23














Forecast cash balance at the end of March 2023 is £36m

NHSBT I&E Full Year Outturn



Forecast outturn of the end of March 2023 is £17.3m. Driven by above plan Blood Supply and ODT expenditure, partially offset by surpluses in Clinical Services and Blood/Group Change Programme

2022/23 NHSBT Financial Performance Headlines – October 2022

Year to Date	£7.4m surplus vs £0.2m budget deficit	Blood/Group +£8.0m	Lower transformation spend, only partially offset by Blood Supply pressures.	
		Plasma -£0.2m	The adverse position reflects an increase in funding available to c/fwd. into 2023/24, arising from lower than expected overhead costs charged (and with the off-setting benefit) through the ABC contribution statement.	
		Clinical Services +£0.1m	Increased activity combined with a high rate of unfilled vacancies, offset by transformation spend (budget profiled into M12)	
		OTDT - £0.4m	ODT (£0.0m) – planned transformation spend offset by activity based underspends TES (-£0.4m) – Cornea income shortfall.	
Full Year Forecast (at Q2)	£17.3m deficit forecast vs £8.1m deficit budget	Blood/Group -£6.4m	Pressures in Blood Supply, partially offset by Change Programme underspends – detail on 5 & 6.	
		Plasma -£0.3m	ABC allocation £0.3m lower than budget estimates (carry forward as cash to 2023/24).	
		Clinical Services +£1.9m	Lower costs due to unfilled vacancies and reduced transformation spend.	
		OTDT -£4.4m	ODT (-£3.4m) – Transformation & DCD Hearts funded from cash (agreed with DHSC). TES (-£1.0m) – Cornea activity lower than plan.	
Cash and Debtors	Cash balance £79m	Debtor Days	17 days – ahead of target (22 days)	
		90+ day overdues	£0.7m (within £0.5m - £1.0m target range).	
		Cash	Cash balance forecast at the end of March 2023 is £36m. Notionally; Blood £11.5m, CS £7.5m, ODT £5.3m, Plasma £12.1m	


Arrow direction indicates the direction of performance vs previous month. Colour demonstrates performance against standards and expectations

NHSBT Summary I&E statement - October 2022

Oct			WTE		Year to Date			Full Year			Variance
Budget	Actual	Variance	Budget	Actual	Budget	Actual	Variance	Prev. Yr Actual	Budget	Q2 Forecast	Variance
1,036	933	(102)			7,250	6,533	(716)	11,461	12,428	11,200	(1,228)
25,581	25,342	(239)			178,983	178,800	(182)	292,274	306,827	306,827	0
293	401	108			2,036	2,427	392	3,864	3,512	4,087	575
503	426	(77)			3,571	4,027	457	5,272	6,091	6,387	296
27,413	27,102	(311)			191,839	191,788	(50)	312,872	328,857	328,501	(357)
(117)	1,399	1,516		0	770	668	(102)	(2,305)	0	(500)	(500)
(13,718)	(14,827)	(1,109)		2,462	(96,663)	(100,337)	(3,674)	(163,543)	(163,952)	(171,851)	(7,900)
(15,426)	(15,021)	406		1,221	(106,770)	(102,168)	4,602	(168,879)	(182,936)	(184,540)	(1,604)
(2,504)	(655)	1,849		0	(9,310)	(2,119)	7,191	(12,213)	(16,999)	(13,058)	3,941
(31,765)	(29,103)	2,662		3,683	(211,974)	(203,956)	8,018	(346,940)	(363,886)	(369,949)	(6,063)
(4,352)	(2,002)	2,351		3,683	(20,135)	(12,168)	7,967	(34,068)	(35,029)	(41,448)	(6,420)
Blood and Group Total											
Plasma for Medicine											
1,176	1,242	67			8,229	8,852	624	29,483	14,107	10,803	(3,304)
682	801	119			4,091	4,070	(21)	1	7,500	7,500	0
1,857	2,043	186			12,320	12,922	602	29,484	21,607	18,303	(3,304)
0	0	0		0	0	0	0	1,076	0	0	0
(883)	(1,244)	(361)		122	(6,175)	(6,953)	(777)	(29,484)	(16,493)	(9,472)	1,504
(883)	(1,244)	(361)		122	(6,175)	(6,953)	(777)	(28,408)	(16,493)	(13,489)	3,004
974	799	(175)		122	6,144	5,969	(175)	1,076	5,113	4,813	(300)
Plasma for Medicine Total											
Clinical Services											
374	347	(27)			2,619	2,428	(191)	4,162	4,489	4,162	(327)
6,329	5,880	(449)			41,748	41,580	(168)	69,057	72,420	73,017	597
6,703	6,226	(477)			44,367	44,008	(359)	73,219	76,909	77,179	270
(5,514)	(5,333)	181		803	(38,431)	(37,202)	1,229	(59,448)	(65,839)	(65,157)	681
0	(115)	(115)		0	0	(811)	(811)	(1,671)	(3,751)	(2,801)	950
(5,514)	(5,447)	66		803	(38,431)	(38,013)	417	(61,119)	(69,590)	(67,959)	1,631
1,189	779	(410)		803	5,936	5,994	58	12,101	7,319	9,220	1,901
Clinical Services Total											
Organ Donation & Transplantation											
6,665	6,757	92			46,656	46,708	51	81,504	79,983	81,316	1,334
170	170	0			1,191	1,191	0	0	2,041	2,041	0
284	227	(57)			1,986	2,043	57	1,921	3,404	3,912	508
7,119	7,154	35			49,833	49,941	108	83,425	85,428	87,270	1,842
(5,741)	(5,437)	304		490	(42,087)	(41,145)	941	(63,376)	(71,926)	(72,080)	(154)
(362)	(355)	7		30	(2,535)	(3,576)	(1,041)	(10,500)	(4,488)	(9,550)	(5,063)
(6,103)	(5,792)	311		30	(44,622)	(44,721)	(99)	(73,876)	(76,414)	(81,630)	(5,216)
1,016	1,362	346		520	5,211	5,220	9	9,550	9,015	5,640	(3,375)
ODT Total											
Tissues and Eye Services											
1,627	1,422	(205)			9,923	9,426	(497)	15,062	17,937	16,921	(1,016)
46	42	(5)			323	292	(32)	0	554	500	(54)
1,673	1,464	(209)			10,246	9,718	(528)	15,062	18,491	17,421	(1,070)
(1,099)	(1,205)	(105)		153	(7,628)	(7,543)	84	(12,468)	(13,043)	(12,971)	72
(1,099)	(1,205)	(105)		153	(7,628)	(7,543)	84	(12,468)	(13,043)	(12,971)	72
574	259	(315)		153	2,618	2,174	(444)	2,595	5,449	4,450	(998)
TES Total											
NHSBT Summary											
44,765	43,989	(776)			308,605	308,377	(227)	514,063	531,293	528,673	(2,619)
(45,364)	(42,791)	2,573		5,281	(308,830)	(301,187)	7,643	(522,810)	(539,426)	(545,998)	(6,572)
(599)	1,198	1,796		5,281	(225)	7,191	7,416	(8,747)	(8,133)	(17,325)	(9,192)
NHSBT Surplus/(Deficit)											

Blood and Group - October 2022

Blood Supply (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Blood and Component Income			179.0	178.8	(0.2)	306.8	306.8	0.0
Other Blood Supply Income			2.0	2.4	0.4	3.5	4.1	0.6
Total Income			181.0	181.2	0.2	310.3	310.9	0.6
Cost of Sales - Blood Component Stock Movement			0.8	0.7	(0.1)	0.0	(0.5)	(0.5)
Blood Donation	1,420	1,453	(44.8)	(46.4)	(1.6)	(75.3)	(79.6)	(4.3)
Manufacturing, Testing & Issue	732	720	(38.9)	(39.8)	(0.9)	(66.4)	(68.6)	(2.1)
Logistics	310	311	(13.0)	(14.1)	(1.1)	(22.2)	(23.7)	(1.5)
Total Expenditure	2,462	2,484	(95.9)	(99.7)	(3.8)	(164.0)	(172.4)	(8.4)



Blood Supply Operating Surplus/(Deficit)	2,462	2,484	85.1	81.6	(3.6)	146.4	138.6	(7.8)
Group Services (incl. Change Programme)	1,221	1,153	(105.3)	(93.7)	11.5	(181.4)	(180.0)	1.4
Blood and Group Surplus/(Deficit)	3,683	3,637	(20.1)	(12.2)	8.0	(35.0)	(41.4)	(6.4)

Group Services detail on page 6

Year to date, Blood Supply are reporting £3.8m adverse cost variance against plan driven by a combination of factors;

- Impact of the higher than budget pay inflation
- Higher use of overtime and temporary staff in Collections and Manufacturing
- Inflationary fuel pressures and increased usage of couriers

The full year effect of these pressures are reflected in the forecast outturn. Combining these with the planned productivity savings in collections that will no longer be delivered and the latest resourcing plans to increase headcount in response to the ongoing stock challenge, Blood Supply are expected to finish the year significantly higher than budget.

Group Services - October 2022

Group Services (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			7.2	6.5	(0.7)	12.4	11.2	(1.2)
Group Services Income			1.0	1.0	0.1	1.7	2.0	0.3
Medical			0.9	1.3	0.4	1.6	1.6	0.0
Research & Development			1.6	1.7	0.0	2.8	2.8	0.0
Total Income			10.8	10.6	(0.3)	18.5	17.6	(0.9)
Chief Executive and Board	4	3	(0.5)	(0.4)	0.0	(0.8)	(0.8)	(0.0)
Donor Experience	191	171	(14.6)	(13.8)	0.8	(23.9)	(26.9)	(3.0)
Quality	129	131	(5.0)	(4.7)	0.3	(8.6)	(8.4)	0.2
Estates & Facilities	80	77	(28.8)	(28.1)	0.7	(49.0)	(49.7)	(0.7)
Finance	111	96	(4.2)	(4.2)	0.0	(7.3)	(7.5)	(0.3)
Strategy and Transformation	14	10	(0.6)	(0.6)	(0.0)	(1.0)	(1.1)	(0.1)
People	153	157	(6.4)	(6.1)	0.4	(11.0)	(11.6)	(0.5)
Digital, Data and Technology Services	301	265	(25.2)	(22.3)	2.9	(44.3)	(41.1)	3.2
Research & Development	47	39	(3.7)	(3.7)	0.1	(6.3)	(6.3)	(0.0)
Medical	193	182	(10.4)	(10.3)	0.1	(18.0)	(17.6)	0.5
Miscellaneous and Capital Charges	0	0	(7.3)	(7.9)	(0.6)	(12.5)	(13.4)	(0.9)
Total Expenditure	1,221	1,130	(106.8)	(102.2)	4.6	(182.9)	(184.5)	(1.6)
Operating Surplus/(Deficit)	1,221	1,130	(95.9)	(91.6)	4.3	(164.4)	(167.0)	(2.5)
Change Programme	0	23	(9.3)	(2.1)	7.2	(17.0)	(13.1)	3.9
Group Services Surplus/(Deficit)	1,221	1,153	(105.3)	(93.7)	11.5	(181.4)	(180.0)	1.4

Year to date, Group Services (excluding the Change Programme) is reporting a £4.3m positive variance against plan. This predominantly reflects underspends reported in DDTS, driven by unfilled vacancies (36 under established) and the re-categorisation of BTM expenditure to capital.

As per the forecast reported at Q2, this favourable position will reverse, with increased pressures profiled throughout the remainder of the year. Including;

- super inflated estate utility costs (-£0.6m)
- Estate development works profiled in Q4 (-£0.5m)
- BAU direct marketing catch up and increased activity to support Blood stocks levels (-£3.8m)
- unfunded National Insurance levy (-£0.5m)
- selling of Annual Leave (-£0.5m)

The latest transformation plan has been reduced from £17m down to c£12m (£13m reported in Q2 forecast). This implies there will be further £10m of spend over the next 5 months. This will need to be closely monitored against planned milestones at programme and project level.

Clinical Services - October 2022 (operating contributions - pre ABC analysis)

(£)m	WTE		Year to Date Actual			Full Year Forecast		
	Budget	Actual	Budget	Actual	Variance	Budget	Fcst.	Variance
Red Cell Immunohematology (inc Reagents and IBGRL)								
Income			13.1	13.1	0.0	22.6	22.5	(0.1)
Expenditure			(10.1)	(9.6)	0.5	(17.2)	(16.8)	0.4
RCI - direct contribution	250	228	3.1	3.5	0.5	5.3	5.6	0.3
Histocompatibility & Immunogenetics								
Income			9.3	9.6	0.3	16.0	16.0	0.1
Expenditure			(9.2)	(9.0)	0.1	(15.7)	(15.7)	0.0
H&I - direct contribution	177	170	0.1	0.5	0.4	0.3	0.4	0.1
Pathology Total - WTE / direct contribution								
	427	398	3.1	4.0	0.9	5.6	6.0	0.4
Therapeutic Apheresis Services								
Income			6.9	8.0	1.2	11.8	13.2	1.4
Expenditure			(5.5)	(6.0)	(0.5)	(9.4)	(10.0)	(0.6)
TAS - direct contribution	99	100	1.4	2.0	0.6	2.5	3.2	0.7
Cord Blood Bank and British Bone Marrow Registry								
Income - prices			4.5	4.0	(0.5)	7.6	7.4	(0.2)
Expenditure			(2.0)	(1.8)	0.2	(3.4)	(3.2)	0.2
SCGT - direct contribution	46	45	2.5	2.1	(0.4)	4.2	4.2	0.0
CBC								
Income			2.6	1.3	(1.4)	4.4	3.2	(1.2)
Expenditure			(2.1)	(2.5)	(0.4)	(3.6)	(3.6)	(0.0)
CBC - direct contribution	37	34	0.5	(1.2)	(1.8)	0.8	(0.4)	(1.2)
Cellular & Molecular Therapies (exc CBC)								
Income			7.9	8.0	0.1	14.4	14.5	0.1
Expenditure			(6.1)	(5.5)	0.6	(10.4)	(9.9)	0.5
CMT I&E	108	101	1.9	2.5	0.6	4.0	4.6	0.6
CAGT Total - WTE / direct contribution								
	290	280	6.3	5.4	(0.9)	11.4	11.6	0.2
Transfusion excl. R&D / Medical (within Group Services)								
	39	35	(0.7)	(0.5)	0.2	(1.2)	(1.2)	(0.0)
DTS Management								
	46	35	(2.8)	(2.2)	0.6	(4.8)	(4.4)	0.4
TOTAL - WTE / Operating Surplus/(Deficit)								
	803	747	5.9	6.8	0.9	11.1	12.0	0.9
Change Programme								
	0	6	0.0	(0.8)	(0.8)	(3.8)	(2.8)	1.0
TOTAL - WTE / Clinical Services Surplus/(Deficit)								
	803	753	5.9	6.0	0.1	7.3	9.2	1.9

At the end of October, Clinical Services (pre ABC analysis) is reporting £0.9m ahead of plan (excluding change programme). This is predominately driven by higher income in TAS and H&I combined with vacancies reported within the Division.

Summary by Business Unit:

RCI; driven primarily by unfilled vacancies in the first half of they year, with this expected to remain in place going into the second half of the year.


H&I; contribution above plan driven by strong service performance year to date, with the latest forecast assuming that this higher run rate will flatten back in line with plan over the remainder of the year.

TAS; year to date, TAS are reporting favourable activity variances in Photopheresis and Red Cell exchange, resulting in a positive position against plan. The forecast expects activity to continue to be ahead of plan.

CBC; adverse position against plan due to slippages in high value contracts and the up front purchase of stock

Cord Blood Bank and Bone Marrow Registry; Both cord blood issues and BBMR harvest behind plan. The latest forecast does not expect Cord activity to achieve plan generating a worsening year end position. However BBMR harvest are expected to achieve £ plan with an increased mix of international issues.

CMT; underspends reflect vacancies, predominately in ACT.



Note: Excludes Medical and R&D funding.

Organ Donation and Transplant – October 2022

ODT I&E (£)m	WTE		Year to Date Actual			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			40.5	40.2	(0.3)	69.4	69.0	(0.4)
Other UK Health Authorities Funding			7.4	7.7	0.3	12.6	14.3	1.7
NHSE Funding			2.0	2.0	0.1	3.4	3.9	0.5
Total Funding			49.8	49.9	0.1	85.4	87.3	1.8
Operating Expenditure	490	461	(42.1)	(41.1)	0.9	(71.9)	(72.1)	(0.2)
Transformation	30	25	(2.5)	(3.6)	(1.0)	(4.5)	(9.6)	(5.1)
Total Expenditure	520	486	(44.6)	(44.7)	(0.1)	(76.4)	(81.6)	(5.2)
ODT Surplus/(Deficit)	520	486	5.2	5.2	0.0	9.0	5.6	(3.4)
Direct contribution to Group Services						(10.8)	(10.8)	0.0
ODT Deficit (funded by cash)						(1.8)	(5.2)	(3.4)

The ODT funding envelope for 2022/23 is based on flat funding from DHSC. The resulting deficit at operational level (£1.8m) will be met from cash reserves.

The forecast deficit reflects transformation which will be funded by cash reserves carried forward from 2021/22. This also includes DCD hearts expenditure, where we are awaiting a decision on additional funding to meet the in year costs (£3.6m).

Going into 2023/24 the underlying deficit is set to increase further, reflecting an incremental increase to activity (per the ODT strategy) and inflation pressures vs flat funding over the SR21 period. This funding gap will need to be addressed well in advance of 2023/24.

Tissue and Eye Services – October 2022

	TES I&E		WTE		Year to Date Actual			Full Year Forecast		
	(£)m		Bud.	Per Act.	Bud.	Act.	Var.	Budget	Fcst.	Variance
Income					10.2	9.7	(0.5)	18.5	17.4	(1.1)
Cost of Sales					(0.3)	(0.2)	0.1	(0.5)	(0.5)	0.0
Expenditure			153	144	(7.3)	(7.3)	(0.0)	(12.5)	(12.5)	0.1
Surplus/(Deficit)			153	144	2.6	2.2	(0.4)	5.4	4.5	(1.0)

Year to date, TES are reporting an income shortfall against plan, primarily driven by lower Cornea activity reported in Q2. The forecast implies that this lower run rate will continue throughout the remainder of the year.

Plasma for Medicine - October 2022

Plasma for Medicine (£)m	WTE		Year to Date			Full Year Forecast		
	Bud.	Act.	Bud.	Act.	Var.	Bud.	Fcst.	Var.
Programme Funding			8.2	8.9	0.6	14.1	10.8	(3.3)
Plasma for Diagnostics Income			4.1	4.1	(0.0)	7.5	7.5	0.0
Expenditure	122	139	(6.2)	(7.0)	(0.8)	(16.5)	(13.5)	3.0
Programme Surplus/(Deficit)	122	139	6.1	6.0	(0.2)	5.1	4.8	(0.3)

For 2022/23, the Plasma plan is fully funded by a combination of cash reserves and Plasma for Diagnostics income.

The 2022/23 budget envelope estimated a group service contribution of £5.1m, however, ABC analysis/allocation has resulted in an overhead allocation of £4.8m. The balance (£0.3m) will be treated as increased funding carried forward into 2023/24.

Cash Flow – as at October 2022

	Actual Apr-22 £k	Actual May-22 £k	Actual Jun-22 £k	Actual Jul-22 £k	Actual Aug-22 £k	Actual Sep-22 £k	Actual Oct-22 £k	Forecast Nov-22 £k	Forecast Dec-22 £k	Forecast Jan-23 £k	Forecast Feb-23 £k	Forecast Mar-23 £k	Total £k
Opening bank balance	64,676	72,432	75,293	69,908	89,346	85,291	85,549	78,791	79,701	74,801	72,866	58,616	64,676
Receipts													
Debtors & Other Receipts	33,604	39,970	34,671	34,788	36,027	37,197	40,547	38,104	38,256	39,221	39,490	40,414	452,290
Revenue Cash Limit	0	0	0	23,833	5,958	5,958	5,958	5,958	5,958	5,958	5,958	5,868	71,410
Revenue Cash Limit - Pensions Uplift	0	0	0	3,680	920	935	935	933	933	933	931	1,000	11,200
Capital Cash Limit	0	0	0	3,000	0	0	0	4,000	2,000		3,000	3,000	15,000
Total Receipts	33,604	39,970	34,671	65,301	42,905	44,090	47,440	48,996	47,148	46,113	49,380	50,283	549,900
Payments													
Staff Expenses	6,743	21,016	21,338	21,413	20,986	23,460	24,359	24,452	24,567	25,838	24,528	32,391	271,090
Other Revenue Payments	18,359	15,949	18,378	24,022	25,932	19,396	18,999	23,134	26,481	21,009	26,665	32,956	271,282
Capital Charges Less DH Credit Due	0	0	0	0	0	0	10,437	0	0	0	10,437	0	20,874
Capital Payments	746	144	340	427	42	975	403	500	1,000	1,200	2,000	7,222	15,000
Total Payments	25,848	37,109	40,055	45,863	46,961	43,832	54,198	48,086	52,048	48,047	63,630	72,569	578,246
Closing bank balance	72,432	75,293	69,908	89,346	85,291	85,549	78,791	79,701	74,801	72,866	58,616	36,330	36,330

Debtor Days (Target is 22 days)	17	14	13	18	17	19	17
YTD BPPC By Value % (Target is 95%)	86.9%	91.1%	93.5%	94.6%	93.4%	93.7%	93.8%
YTD BPPC By Number % (Target is 95%)	92.8%	93.1%	93.3%	93.5%	93.4%	93.3%	93.2%

Overdue Debtors NBS/ODT £000's	1-30 Days overdue £000's	31-60 Days overdue £000's	61-90 Days overdue £000's	>90 Days overdue £000's	Total Overdue £000's
Total Overdue Debtors	5,370	1,921	621	709	8,622

Top 5 > 90 days Overdue Debtors £000's	Sep-22		Oct-22	
	>90 Days overdue £000's	Total Overdue £000's	>90 Days overdue £000's	Total Overdue £000's
KINGSTON HOSPITAL NHS FOUNDATION TRUST	105	425		
GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST	84	734	93	228
LEEDS TEACHING HOSPITALS NHS TRUST	92	486	82	272
IMPERIAL COLLEGE HEALTHCARE NHS TRUST			64	362
HAMPSHIRE HOSPITALS NHS FOUNDATION TRUST			57	180
ISLE OF WIGHT NHS TRUST	98	250	44	133
CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST	77	307		
Total 5 Overdue Debtors	456	2,202	340	1,175
Other Debtors	466	9,125	370	7,447
Total Overdue Debtors	922	11,326	709	8,622

Notional Split	£m
Blood	11.5
Clinical Services	7.5
ODT	5.3
Plasma	12.1
NHSBT Total	36.3

>90 DAYS OVERDUE	Profile by Month													
	Actual Apr-22 £000s	Actual May-22 £000s	Actual Jun-22 £000s	Actual Jul-22 £000s	Actual Aug-22 £000s	Actual Sep-22 £000s	Actual Oct-22 £000s	Actual Nov-22 £000s	Actual Dec-22 £000s	Actual Jan-23 £000s	Actual Feb-23 £000s	Actual Mar-23 £000s		
	Target Range Between £0.5m and £1.0m													
Ledger Balance at month end	330	413	686	680	536	922	709							

Contribution Statement– as at October 2022

Post allocation of costs via the ABC model

Year to date Actual £m	Blood & Components inc. R&D	Plasma	Pathology		CAGT				TES	ODT	NHSBT
			RCI	H&I	CMT	CBC	SCDT	TAS			
Income/Funding											
Prices	180.9	0.0	12.4	8.4	7.8	0.0	2.5	7.8	9.4	0.0	229.2
Central Funding from DHAs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	7.5
Grant in Aid (DHSC Funding)	5.0	9.0	0.2	1.1	0.1	0.0	1.5	0.1	0.4	40.9	58.3
Other	4.4	4.1	0.7	0.2	0.3	1.3	0.0	0.3	0.0	2.2	13.4
Total Income/Funding	190.4	13.0	13.3	9.7	8.1	1.3	4.0	8.1	9.9	50.6	308.4
Expenditure											
Variable Costs	(21.5)	(0.4)	(1.1)	(2.3)	(1.2)	(0.9)	(0.1)	(2.4)	(1.6)	(2.1)	(33.6)
Variable Contribution	168.8	12.6	12.1	7.4	6.9	0.4	3.9	5.7	8.3	48.6	274.8
Direct Costs	(77.0)	(6.5)	(7.7)	(4.7)	(4.3)	(1.7)	(2.2)	(3.5)	(6.3)	(40.8)	(154.7)
Direct Contribution	91.8	6.1	4.4	2.6	2.6	(1.2)	1.7	2.3	2.0	7.8	120.1
Direct Support Costs	(63.8)	(1.8)	(3.2)	(1.2)	(2.7)	(0.6)	(1.0)	(0.8)	(2.0)	(6.2)	(83.2)
Total Allocated Costs	(162.3)	(8.7)	(12.0)	(8.2)	(8.2)	(3.1)	(3.4)	(6.6)	(9.9)	(49.0)	(271.5)
Total Unallocated Costs	(13.8)	(0.7)	(1.0)	(0.7)	(0.7)	(0.3)	(0.3)	(0.6)	(0.8)	(4.4)	(23.3)
Operating Net Surplus / (Deficit)	14.2	3.6	0.2	0.7	(0.8)	(2.1)	0.4	0.9	(0.9)	(2.8)	13.5
Transformation	(1.9)	-	(0.2)	(0.1)	(0.1)	(0.0)	(0.1)	(0.1)	-	(3.6)	(6.2)
Net Surplus / (Deficit) Inc Transformation	12.3	3.6	0.0	0.6	(0.9)	(2.1)	0.3	0.8	(0.9)	(6.4)	7.3
Budget	6.0	3.5	(0.5)	0.2	(1.9)	(0.4)	0.7	0.3	(0.7)	(7.3)	(0.2)
Variance	6.3	0.1	0.5	0.5	0.9	(1.7)	(0.4)	0.5	(0.1)	0.9	7.5
RAG	G	G	G	G	G	R	R	G	R	G	G

Notes;

Blood at "Green" but results from the favourable group services and change programme position.

CBC – adverse position against plan due to slippages in high value contracts and the up front purchase of stock

Stem Cell and Donation – reporting red as BBMR income and CBB issues are behind plan.

TES – reporting red reflecting lower cornea activity.

i) This report reflects the final version of the ABC model for 2022/23, and includes adjustments arising from a review of cost allocation data since the original indicative draft.

ii) Work is ongoing to develop the model for 2023/24 planning and reporting, which will include further updates.